— Research note —
Ipamorelin
Selective pentapeptide ghrelin receptor agonist investigated as a growth hormone secretagogue with minimal effects on cortisol and prolactin.
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) developed by Novo Nordisk in the late 1990s as a selective agonist of the growth hormone secretagogue receptor (GHSR-1a), also known as the ghrelin receptor. The compound was designed within a medicinal chemistry program aimed at identifying secretagogues that retained the growth hormone-releasing potency of earlier GHRP-class peptides while minimizing off-target effects on the hypothalamic-pituitary-adrenal axis and on prolactin secretion.
In preclinical and early clinical research, ipamorelin has been characterized by a selective growth hormone release profile, with limited effects on cortisol, adrenocorticotropic hormone (ACTH), or prolactin at doses that produced substantial growth hormone responses. This selectivity contrasts with earlier secretagogues such as GHRP-6 (which stimulates appetite via central ghrelin-related pathways) and GHRP-2 (which elevates cortisol and prolactin at active doses), positioning ipamorelin as a useful research probe for isolated growth hormone pulse studies.
The molecule advanced through phase 1 and phase 2 clinical research, including investigations in postoperative ileus and in healthy volunteer pharmacology. Although development for those indications did not lead to regulatory approval, the published literature established the pharmacokinetic and pharmacodynamic profile of the compound in human research populations. Subsequent academic research has used ipamorelin as a tool molecule for studies of growth hormone secretion dynamics, combination pharmacology with GHRH analogs, and ghrelin receptor biology.
The compound is supplied here for laboratory research use only and is not intended for human consumption. Its primary research applications include pituitary pharmacology, ghrelin receptor structure-activity studies, and somatotroph regulation models.
Mechanism
Ipamorelin binds the growth hormone secretagogue receptor type 1a (GHSR-1a), a class A G-protein coupled receptor expressed on pituitary somatotrophs, hypothalamic arcuate nucleus neurons, and several peripheral tissues. Receptor activation couples primarily through Gq to phospholipase C-beta, generating inositol trisphosphate and mobilizing intracellular calcium. This calcium signal triggers exocytosis of stored growth hormone from somatotroph secretory granules.
The selective profile of ipamorelin compared with earlier GHRPs has been attributed to the specific conformational presentation of the pentapeptide at the GHSR-1a binding pocket, with reduced engagement of alternative signaling pathways or off-target receptors implicated in cortisol and prolactin release. When combined with GHRH receptor agonists such as sermorelin or modified GRF (1-29), ipamorelin produces synergistic growth hormone release, reflecting the complementary Gs and Gq signaling pathways activated by the two receptor systems in somatotrophs.
Research history
Ipamorelin was disclosed by Raun and colleagues at Novo Nordisk in 1998 as part of a structure-activity exploration of pentapeptide and hexapeptide growth hormone secretagogues. The molecule was characterized as the most selective member of the GHRP class identified to that point, with growth hormone release potency comparable to GHRP-6 but with minimal cortisol or prolactin response in rat and porcine preclinical models.
Clinical research conducted by Novo Nordisk in the late 1990s and 2000s included phase 1 healthy-volunteer pharmacokinetic studies and phase 2 investigations in postoperative ileus, where ghrelin receptor activation in the gastrointestinal tract was hypothesized to accelerate return of bowel function. The development program for that indication was discontinued in the 2000s.
Subsequent academic research has used ipamorelin extensively in pituitary pharmacology, including studies of GHRH-secretagogue synergy, GHSR-1a signaling bias, and somatotroph adaptation. The compound has been compared with hexarelin, GHRP-2, GHRP-6, and the orally bioavailable secretagogue ibutamoren (MK-677) in head-to-head pharmacological characterizations. Ipamorelin remains one of the most frequently cited reference compounds in studies of selective ghrelin receptor agonism.
References
- Raun K, et al. 1998. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. PMID: 9847237
- Andersen NH, et al. 2001. Structural and functional consequences of two NMR signals in ipamorelin. Biopolymers. PMID: 11459495
- Beck DE, et al. 2014. Safety and efficacy of ipamorelin for the management of postoperative ileus. J Gastrointest Surg.
- Smith RG. 2005. Development of growth hormone secretagogues. Endocr Rev. PMID: 15814848
- Sinha DK, et al. 2008. Beyond the androgen receptor: the role of growth hormone secretagogues. Curr Drug Targets.
- Khatib N, et al. 2014. Ghrelin: ghrelin as a regulatory peptide in growth hormone secretion. J Clin Diagn Res.
Do you have any questions about Ipamorelin?
Pick a path. The research assistant has the full literature context loaded.
Information presented in third-person scientific context. Research use only. Not medical advice; not for human consumption.